Urodynamix and Laborie Medical Technologies to Unveil URO-NIRS Bladder Monitor at the 2007 American Urological Association Annual Meeting

VANCOUVER, British Columbia, May 18, 2007 - Urodynamix Technologies Ltd. (TSX-V:URO) and Laborie Medical Technologies ("Laborie") today announced that the prototype URO-NIRS Bladder Monitor will be on display at the 102nd American Urological Association ("AUA") Annual Meeting and Exhibition in Anaheim, California from May 19-22, 2007. The AUA Annual Meeting is the world's largest meeting of urologic professionals, with more than 10,000 urologists and health care professionals and 350 exhibitors showcasing their urological products or services.

In advance of FDA clearance, Urodynamix and Laborie will unveil a prototype of the URO-NIRS Bladder Monitor with Laborie's Urodynamics System as a fully integrated platform. The integrated device, which is currently under investigation and not available for sale, will be exhibited at the Laborie booth in the Anaheim Convention Center (AUA Booth 2700).

Urodynamix is developing the integrated URO-NIRS Bladder Monitor for non-invasive hospital-based urodynamics testing and related clinical applications, including the diagnosis and characterization of urinary incontinence, lower urinary tract symptoms and erectile dysfunction. In May 2007, Urodynamix entered into a worldwide licensing agreement with Laborie to distribute URO-NIRS technology in acute care settings (see news release dated May 17, 2007 for details).

Subject to regulatory approvals and Laborie's launch program, Urodynamix expects the URO-NIRS Bladder Monitor product to be ready for launch in the US, Europe and Canada by the end of 2007.

About AUA 2007

The American Urological Association's Annual Meeting is the world's largest meeting of urologic professionals. More than 10,000 urologists and health care professionals and 5,000 exhibitors will be in attendance with over 350 exhibitors showcasing their urological products or services.

About Laborie Medical Technologies

Founded in 1982 by Ray Laborie, a Canadian medical device specialist, Laborie Medical Technologies is the leading global manufacturer of urodynamics equipment used in the diagnosis and treatment of incontinence. Laborie's product line consists of the industry's most advanced urodynamics and biofeedback/stimulation systems, patient management software, catheters and disposables. In addition to utilizing the latest advances in technology, Laborie produces and sponsors leading educational courses in urodynamics for doctors, nurses and technicians around the world each year.

Laborie introduced the first computerized Urodynamics (UDS(tm)) processor in 1984, and now claims the largest and most knowledgeable UDS sales force in the world with offices in Ontario, Quebec, Vermont, Belgium and China, and direct sales and distribution networks in 52 countries across North America, Europe and Asia. In addition to an extensive sales force, Laborie's team of over 30 on-staff engineers, field technicians and UDS nurses install UDS systems, train users, and work in concert with leading clinician-researchers and local universities. These resources ensure that Laborie can bring the talent and technical knowledge necessary to assure that its products incorporate the most recent advancements and also reflect the practical realities of the typical urology or urogynecology clinic.

About Urodynamix Technologies Ltd.

Urodynamix is developing a portfolio of non-invasive diagnostic products for a variety of large and growing global markets. The Company is currently developing NIRS applications for urological conditions in men and women, intra-abdominal hypertension and compartment syndrome, erectile dysfunction and vascular diseases. The Company's disruptive technology has the potential to affect the diagnosis and treatment of more than 200 million people worldwide.

On behalf of the Board,

"Barry Allen"
President & CEO
Urodynamix Technologies Ltd.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Craig Pamplin, PhD, CFA
Director, Corporate Development and Communications Urodynamix Technologies Ltd.
Tel: (604) 638-0247
Email: cpamplin@urodynamix.com
www.urodynamix.com